Gynura procumbens ethanol extract and its fractions contain compounds from group of fatty acids, flavonoids, sesquiterpenoids and product of chlorophyll breakdown which can act as immunodulators in regulating macrophage proliferation. 
Introduction
Gynura procumbens (GP), a tropical plant that belongs to the family Asteraceae, is found extensively in Southeast Asia, particularly in Indonesia, Malaysia, and Thailand (1) . GP reaches a height of 1-3 m and has fleshy stems and ovate-elliptical or lanceolate shaped leaves (2) . In Malaysia, GP is known as Sambung nyawa, which means "prolongation of life" (3) , and eating raw fresh leaves has been scientifically proven to be safe (4) . GP traditionally is used to treat eruptive fever, kidney disease, migraines, constipation, hypertension, diabetes mellitus, and cancer (5) . Intensive studies of GP have shown that it has antiherpes simplex virus (6) , anti-hyperglycaemic (7), antiinflammatory (8) , anti-hyperlipidemic (9) , and blood hypertension reduction (10) capabilities. These beneficial properties may be due to the active chemical constituents of GP, such as flavonoids, saponins, tannins, terpenoids, steroid glycosides, rutin, and kaempferol (7, (10) (11) (12) . Almost 75% of plant-based therapeutic drugs used worldwide originally are traditional-based medicines (13) , and there is growing interest in discovering herbal medicines for management of various diseases. Therefore, the safety and potential toxicity of medical plants and edible materials must be determined (5) .
Macrophages are scavenger cells that play an important role in regulating inflammatory responses by destroying viruses, bacteria, and parasites via phagocytosis process (14) . In addition, macrophages also remove apoptotic cells in inflamed tissues (14) . When macrophages ingested particles or any foreign agent, they trigger secretion of pro-inflammatory cytokines such as Interleukin-1 beta (IL-1β), IL-6, IL-12 and tumor necrosis factor alpha (TNF-α). It also can produce anti-inflammatory cytokines such as IL-10 and tumor growth factor beta (TGF-β) (14) . However, the ingestion of apoptotic cells does not stimulate its activation (15) . Few studies of the bioactive constituents of GP extracts and their effects on phagocytic cells (i.e., macrophages) have been conducted. The current study was carried out to identify the bioactive secondary metabolites that may influence the cell viability of mouse murine macrophage cells (RAW 264.7) treated with GP ethanol extract and its fractions.
Materials and Methods

Plant material
Fresh leaves of GP were purchased from Herbagus Sdn. Bhd. at Kepala Batas, Penang, Malaysia and identified by a botanist from the Herbarium, School of Biological Sciences, Universiti Sains Malaysia. The plant was identified as GP and the voucher number was recorded as USM Herbarium 11753.
Preparation of GP leaf extract Fresh GP leaves were washed with water to remove dirt prior to drying at 40°C for a week. The dried leaves were pulverized using a herb grinder. The leaf powder was extracted repeatedly for 3 days with ethanol (97%) (Thermo Fisher, San Diego, CA, USA) using the maceration method at a ratio of 1:10 raw materials to solvent. Macerated raw material was stirred occasionally and fresh ethanol was replenished every 3 days for 9 days. The extract was filtered through filter paper (Whatman No.1), and the filtrate was concentrated using a rotary evaporator at 45°C. The concentrated extract was lyophilized to obtain the dry powdered extract. The ethanol leaf extract was stored at -20°C until further use.
Fractionation
The ethanol GP leaf extract was subjected to fractionation. First, 20 g of the powdered extract was reconstituted in distilled water for liquid-liquid partition with an equal volume of n-hexane (200 mL x 3 times) in a separating funnel. The separating funnel was shaken gently, and the n-hexane portion was collected. Subsequently, the residue was partitioned with solvents of increasing polarity (chloroform, ethyl acetate, and aqueous). The fractions were concentrated using a rotary evaporator at 45°C and freeze dried to obtain dried fractionated extracts. The fractions were stored at -20°C until further use.
Cell viability assay RAW 264.7 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 1% antibiotics (250 U/mL penicillin, 250 µg/mL streptomycin), and 1% HEPES 1M. The cells were maintained at 37°C in a humidified incubator set at 5% CO 2 . The cells were seeded at a concentration of 1 × 10 4 cells/mL in 96-well plates and incubated at 37°C at 5% CO 2 for 24 hours. After 24 h of incubation, the cells were treated with the GP ethanol extract and its fractions (hexane, chloroform, ethyl acetate, and aqueous) at concentrations ranging between 1 to 100 µg/mL and 0.01 to 10 µg/mL, respectively. The plates were incubated at 37°C at 5% CO 2 for 24, 48, and 72 h. After each respective time of incubation, the medium was removed and 10 µL of PrestoBlue (PB) reagent (Invitrogen, Carlsbad, CA, USA) and 90 µL of fresh medium were added to each well, and the plates were further incubated for 50 minutes. The fluorescence of the color complex was read at 544-590 nm using a FLUOstar ® Omega microplate reader (BMG LABTECH, Ortenberg, Germany).
Liquid chromatography-mass spectrometry analysis of the GP ethanol extract and its fractions The GP ethanol extract and its fractions were dissolved in ethanol, with the exception of the aqueous fraction, which was dissolved in distilled water (50%) and ethanol (50%). The samples were centrifuged at 14000 RPM for 15 minutes, filtered through a 0.45 µm nylon syringe filter, and diluted 10x for analysis. liquid chromatography-mass spectrometry (LC-MS) analysis was performed using an Agilent 1290 Infinity LC system coupled to an Agilent 6520 Accurate-Mass Q-TOF mass spectrometer with a dual ESI source (Santa Clara, CA, USA). Separation was performed using an Agilent Zorbax Eclipse XDB-C18, Narrow-Bore column (2.1 mm x 150 mm x 3.5 µm). The column temperature was 25⁰C, and the auto sampler temperature was programmed at 4⁰C.The mobile phases were 0.1% formic acid in water and 0.1% formic acid in acetonitrile at a flow rate of 0.5 mL/min. Aliquot samples of 1 µL and 2 µL were injected for targeted MS and MS/MS positive and negative modes, respectively. The chromatographic data were processed using Agilent MassHunter Qualitative Analysis software. The identified compounds were verified by comparing with the METLIN metabolomic database.
Statistical analysis
The cell viability results were expressed as mean ± standard error mean (SEM). One-way ANOVA was applied to determine significance between the untreated group vs. treated groups. Analysis was performed by Statistical Package for the Social Sciences (SPSS) software version 19.0, and differences were considered significance at P<0.05. The experiment was performed three times.
Results
The GP ethanol extract and its fractions promote proliferation of RAW264.7 cells The GP ethanol extract and its hexane, chloroform, ethyl acetate, and aqueous fractions stimulated proliferation of RAW264.7 cells, as the percentages of cell viability were above 100% compared to untreated cells. In addition, these extracts had a weak cytotoxic effect on the cells, with an average inhibitory concentration of 90% at 24, 48, and 72 h of incubation ( Figure 1A-E) . However, cell proliferation decreased as extract and fractions concentration, and also time increased (Figure 1A-E) . At 10 µg/mL, the aqueous GP fraction clearly displayed anti-proliferative properties because the cell viability of aqueous GP fraction-treated RAW264.7 cell reduced to 64%, 29% and 4% after 24, 48 and 72 hours of incubation, respectively ( Figure 1B ).
Phytoconstituents identified in the GP ethanol extract and its fractions
The bioactive constituents present in the GP ethanol extract and its fractions were successfully identified using LC-MS. Figure 2 shows the MS chromatograms for positive and negative modes of the GP ethanol extract. Figure 3 displays the MS chromatograms for positive and negative modes of the GP aqueous fraction. Figure  4 shows the MS chromatograms for positive and negative modes of the GP ethanol chloroform fraction. Figure 5 demonstrates the MS chromatograms for positive and negative modes of the GP ethyl acetate fraction. Figure 6 shows the MS chromatograms for positive and negative modes of the GP hexane fraction. LC-MS revealed different types of bioactive phytochemicals with high and low molecular weights in varying quantities present in positive and negative modes of GP ethanol extract and its fractions. The identified compounds of α-9(10)-EpODE, Cpd 45: 9Z,12Z,15E-octadecatrienoic acid, 6E,9E-octadecadienoic acid and Pheophorbide a are presented in both positive and negative modes of GP ethanol extract (Table 1) . Table 2 Table 3 shows the compounds that present in both positive and negative modes of GP chloroform fraction namely 4-(2-hydroxypropoxy)-3,5-dimethyl-Phenol, 11-hydroperoxy-12,13-epoxy-9-octadecenoic acid, decenedioic acid, (-)-12-hydroxy-9,10-dihydrojasmonic (Table 4) . Table 5 listed compounds of harderoporphyrin, 6E,9E-octadecadienoic acid, pheophorbide a and 9Z,12Z,15E-octadecatrienoic acid detected in positive and negative modes of GP hexane fraction. Among them, 9Z, 12Z, 15E-octadecatrienoic acid was present in the GP ethanol extract as well as the hexane and aqueous fractions. In addition, 6E, 9E-octadecadienoic acid and pheophorbide A (Pa) were present in both the GP ethanol extract and the hexane fraction.
Discussion
Treatment of murine macrophages (RAW264.7) with the GP ethanol extract and its fractions may impact cell morphology, growth, death, and disintegration. In this study, cell viability of treated cells was monitored using PB, which is a resazurin-based reagent that acts as a signal for mitochondrial metabolic activity (15) . PB solution is water soluble and non-toxic to the cells, so it is useful for monitoring toxicity of the treatment to the cells in vitro (15) . PB is the fastest known live assay, as the incubation period is only 10 minutes (15) . Changes in cell viability also can be revealed calorimetrically or fluorometrically (15) . Results of the present study showed that treatment with the GP ethanol extract and its fractions stimulated proliferation of RAW264.7 cells but the cell proliferation decreased in a concentration-and time-dependent manner. The effect of the GP ethanol extract, but not the fractions, on immune cells was reported previously. Results of the current study were in agreement with those of a previous study that suggested that the GP ethanol extract stimulates macrophages to clear carbon particles in the animal bloodstream (16) . Our findings also are in line with results of a recent study of the immunomodulatory activity of the GP ethanol leaf extract on mice splenic cells (17) . In that study, treatment with the GP extract at 0.1 and 1.0 μg/mL promoted greater proliferation of CD4+CD25+, CD4+CD62L−, CD4+CD62L+, CD8+CD62L−, andCD8+CD62L+ T cells but reduced proliferation of B220+ cells (17) , whereas the 10 μg/mL dose enhanced the proliferation of B cells (17) . Furthermore, Sriwanthana et al (18) also found that in humans, the GP extract accelerated lymphocyte stimulation, which suggests that GP is a putative immunostimulant. In the current study, the aqueous fraction at concentration of 10 µg/ mL clearly displayed anti-proliferative properties. These results were supported by Lee et al (19) who reported an anti-proliferative effect of the aqueous extract of GP, as it inhibited mesangial cell proliferation via suppression of PDGF-BB and TGF-β expression and modulation of CDK1 and CDK2 expression.
On the other hand, LC-MS was used to identify the bioactive constituents that might be involved in the stimulation of RAW264.7 cells proliferation. Many compounds in the GP ethanol extract and its fractions were identified, and some distinctive bioactive compounds were present in both positive and negative ion modes, such as flavonoids, fatty acids, octadecanoids, porphyrins, sesquiterpenoids (terpenes), a product of chlorophyll breakdown (Pa), trihydroxyflavone, monohydroxybenzoic acid, and hyroxycinnamic acid. 9Z, 12Z, 15E-octadecatrienoic acid from the fatty acid group (linolenic acid) was present in the GP ethanol extract and the hexane and aqueous fractions. This compound may be responsible for inducing proliferation of RAW264.7 cells, as suggested by Ohue-Kitano et al (20) . They studied the effect of α-linolenic acid (ALA) and its gut lactic acid bacteria metabolites 13-hydroxy-9(Z), 15(Z)-octadecadienoic acid (13-OH) and 13-oxo-9(Z),15(Z)-octadecadienoic acid (13-oxo) on the differentiation of M2 macrophages from bone marrow-derived cells (BMDCs) (20) . They showed that treatment of BMDCs with ALA, 13-OH, or 13-oxo in the presence of IL-4 or IL-13 for 24 h induced the expression M2 macrophage markers CD206 and arginase-1 (20) . In an in vivo experiment, they also demonstrated high deposition of M2 macrophages in the lamina propria of the small intestine of C57BL/6 mice treated intragastrically with ALA, 13-OH, or 13-oxo at 1 g/kg of body weight per day for 3 days (20) .
In the current study, 6E, 9E-octadecadienoic acid and (Pa) were identified in both the GP ethanol extract and the hexane fraction. 6E, 9E-octadecadienoic acid may have an effect similar to that of 9Z, 12Z, 15E-octadecatrienoic acid, as they are in the same fatty acid group (linoleic acid). Pa is a product of chlorophyll breakdown (21) , and it may be a potential photosensitizer for photodynamic therapy of human cancer (22) . Bui-Xuan et al (22) also reported that Pa promoted the growth of RAW 264.7 cells, with maximum effect at 1.0 μM after 24, 48, and 72 h of treatment.
Conclusion
The GP ethanol extract and its fractions at certain concentrations may act as potential immunomodulators, as they stimulated macrophage proliferation instead of cell death. This premise was further strengthened by identification of compounds such as linoleic acid and a product of chlorophyll breakdown in the extracts, which previously were shown to promote macrophage proliferation (20, 22) . Diverse biologically active constituents in the GP ethanol extract and its fractions warrant further study to determine their biological and pharmacological properties.
